Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and David Sallman, MD, Assistant Member, Department of Malignant Hematology, Moffitt Cancer Center discuss CAR T as it pertains to clinical advances in leukemia

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center and Bradley McGregor, MD, Clinical Director, Lank Center for Genitourinary Oncology, Professor of Medicine, Harvard Medical School, discuss Checkmate 9ER and other I-O studies as they pertain to the management of RCC patients

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Victoria Villaflor, MD, Clinical Professor, Director Head and Neck Oncology at City of Hope, discuss unresectable stage III Non Small Cell Lung Cancer (www.azioinpractice.com)

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Geoffrey Ku, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center, discuss recent clinical developments in gastric and esophageal cancer

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Sara Hurvitz, MD, Associate Professor of Medicine, Geffen School of Medicine, UCLA, Medical Director, Jonsson Comprehensive Cancer Center Clinical Research Unit, discuss breast cancer patient types, challenges, and treatment advances.

Roy Herbst, MD, and Robert Figlin, MD, discuss the implications of the ADAURA study investigating the use of Tagrisso (osimertinib) in stage I-III EGFR+ NSCLC patients

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Nancy Lin, MD, Associate Professor of Medicine, Harvard Medical School Associate Chief, Division of Breast Oncology Dana-Farber Cancer Institute, discuss novel agents and recent clinical developments in breast cancer

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Edward Garon, MD, Director of Thoracic Oncology Program, Jonsson Comprehensive Cancer Center, Associate Professor of Medicine, David Geffen School of Medicine, UCLA, discuss promising agents in development for the management of NSCLC from ASCO20

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and David Ilson, MD, Attending Physician, Memorial Sloan Kettering Cancer Center, Professor of Medicine, Weill Cornell Medical College, discuss the progress in colon and rectal cancer presented at ASCO20

Robert Figlin, MD, Steven Spielberg Family Chair in Hematology-Oncology, Cedars-Sinai Medical Center, and Constantine Tam, MD, Haematologist and Disease Group Lead, Low Grade Lymphoma and Chronic Lymphocytic Leukemia, Peter MacCallum Cancer Centre, discuss the progress in Waldenstrom macroglobulinemia from ASCO20